FOLH1 and prostate carcinoma: For example, one study utilized dual recognition of prostate stem cell antigen (PSCA) (with an anti-PSCA scFv-CD3ζ to provide signal 1) and prostate-specific membrane antigen (PSMA) (with an anti-PSMA scFv-CD28-4-1BB to provide signal 2) to target prostate cancer [32].